HRTX vs. MREO, ESPR, ANNX, NGNE, STTK, VRCA, BMEA, KRRO, PEPG, and TBPH Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Mereo BioPharma Group (MREO), Esperion Therapeutics (ESPR), Annexon (ANNX), Neurogene (NGNE), Shattuck Labs (STTK), Verrica Pharmaceuticals (VRCA), Biomea Fusion (BMEA), Korro Bio (KRRO), PepGen (PEPG), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical preparations" industry.
Heron Therapeutics (NASDAQ:HRTX ) and Mereo BioPharma Group (NASDAQ:MREO ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, community ranking, profitability, earnings and analyst recommendations.
Mereo BioPharma Group has a net margin of 0.00% compared to Heron Therapeutics' net margin of -61.28%.
In the previous week, Mereo BioPharma Group had 4 more articles in the media than Heron Therapeutics. MarketBeat recorded 13 mentions for Mereo BioPharma Group and 9 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.60 beat Mereo BioPharma Group's score of 0.48 indicating that Heron Therapeutics is being referred to more favorably in the media.
80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 6.4% of Heron Therapeutics shares are owned by insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Heron Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 71.88%. Mereo BioPharma Group has a consensus target price of $6.50, suggesting a potential upside of 103.13%. Given Mereo BioPharma Group's higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Heron Therapeutics.
Heron Therapeutics received 623 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 72.34% of users gave Mereo BioPharma Group an outperform vote while only 69.01% of users gave Heron Therapeutics an outperform vote.
Heron Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Mereo BioPharma Group has lower revenue, but higher earnings than Heron Therapeutics.
Summary Heron Therapeutics and Mereo BioPharma Group tied by winning 7 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Heron Therapeutics Competitors List
Related Companies and Tools
